Antibodies are proteins produced by the immune system in response to infection, often within the first week of post-symptoms onset. There are several forms of antibodies: IgG, IgM, IgA, as well as other forms. However, not all antibodies are created equal; some are considered to be binding antibody and some are neutralizing. A neutralizing antibody

Aculabs would like to take this time to update all client facilities regarding a number of key issues that our industry faces in the coming week(s). Please take a moment to read the following measures. 2 Week Testing Pilot and BinaxNOW Test Cards November 20th, 2020 - The State of New Jersey

In reviewing our turnaround times for our various COVID-19 testing options, it recently came to our team's attention that some client facilities are not inputting in the proper Collection Date and Time.  The collection date and time are taken from the COLLECTION DATE and COLLECTION TIME fields from the web portal when placing an order.

10/09/20 NOTICE: PLEASE READ OUR MEMO REGARDING OUR EMPLOYEE SAFETY PROTOCOLS August 26, 2020 - CMS has issued CMS-3401-IFC, "Additional Policy and Regulatory Revisions in Response to the COVID-19 Public Health Emergency related to Long-Term Care (LTC) Facility Testing Requirements and Revised COVID-19 Focused Survey Tool", expanding standards that LTCs must follow to prevent

April 7, 2020 - Aculabs will immediately begin performing COVID-19 screenings via the BioGX SARS-CoV-2 Reagents for BD MAX™ System, a real-time RT-PCR test intended for the qualitative detection of nucleic acid from SARS-CoV-2. The ability to perform screenings will allow for result reporting within 24 hours, vital to the high-risk populations Aculabs services as

4/7/20: Aculabs now offers SARS-CoV-2 testing for COVID-19 - Read More The New Jersey Department of Health has announced, starting on February 28, 2020, that the CDC SARS-CoV-2 real-time RT-PCR test will now be available at New Jersey Public Health and Environmental Laboratories. For the convenience of client facilities, Aculabs will participate in shipping the

Above: The CPP diplomates pose at the CPOCT Division & Awards Meeting, Tuesday, August 6, 2019, at the 2019 American Association for Clinical Chemistry (AACC) Annual Scientific Meeting & Clinical Lab Expo (Anaheim, CA); Dr. Rita Khoury, Aculabs' Lab Director, stands in the center. Photo courtesy of Medical Lab Observer. In August 2019,

Aculabs is pleased to announce our newest offering; a molecular diagnostic test for the direct qualitative detection and differentiation of enteric pathogens performed on the BD MAXTM Molecular system. Acute Gastroenteritis affects 1 in 6 Americans, causing approximately 179 million outpatient visits, 500,000 hospitalizations and >5,000 deaths each year.  Pathogens causing Infectious Gastroenteritis are primarily

The Centers for Disease Control and Prevention have issued new recommendations for TB Testing in the expectation that ongoing shortages will continue until the new year. These new recommendations have been made in response to an anticipated shortage for Aplisol, a purified-protein derivative (PPD) tuberculin antigen approved by the US Food and Drug Administration for

Aculabs is proud to announce that we've been awarded our New York State laboratory permit by the New York State Department of Health. Effective June 6th, 2019, Aculabs can begin onboarding and servicing clients within NYS. Our customer service team will begin getting in touch with those who have expressed interest in acquiring Aculabs' services.